No association between common chemokine and chemokine receptor gene variants and prostate cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 12, 2008, Pages 3615-3617

  Petersen, Desiree C ^a,c   Severi, Gianluca ^d,e   Hoang, Hoa N ^d   Padilla, Emma J D ^c   Southey, Melissa C ^e   English, Dallas R ^d,e   Hopper, John L ^e   Giles, Graham G ^d,e   Hayes, Vanessa M ^a,b,c  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d CANCER EPIDEMIOLOGY CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; RANTES; STROMAL CELL DERIVED FACTOR 1;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

CASE-CONTROL STUDIES; CHEMOKINES; GENETIC VARIATION; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE;

EID: 57449087871     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0896     Document Type: Article

References (19)

1. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol 2008;18:315-9.
2. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
3. Hold GL, El-Omar EM. Genetic aspects of inflammation and cancer. Biochem J 2008;410:225-35.
4. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
5. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A 1999;96:4581-5.
6. Nickel RG, Casolaro V, Wahn U, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000;164:1612-6.
7. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998;279:389-93.
8. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
9. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.
10. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2-64I polymorphism affects stability of CCR2A isoform. AIDS 2004;18:729-38.
11. 3CR1. Science 2000;287:2274-7.
12. 3CR1 and risk of HIV disease. Science 2000;290:2031.
13. Hirata H, Hinoda Y, Kikuno N, et al. CXCL12 G180A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 2007;13:5056-62.
14. Severi G, Giles GG, Southey MC, et al. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst 2003;95:818-24.
15. Sham P. Statistics in human genetics. Applications of statistics. London: Arnold; 1998.
16. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-22.
17. Breslow NE, Day NE. Statistical methods in cancer research. vol. 1 - The analysis of case-control studies. IARC Scientific Publications. Lyon: IARC; 1980.
18. Maho A, Bensimon A, Vassart G, Parmentier M. Mapping of the CCXCR1, CX3CR1, CCBP2 and CCR9 genes to the CCR cluster within the 3p21.3 region of the human genome. Cytogenet Cell Genet 1999;87:265-8.
19. Ioannidis JP, Ntzani EE, Trikalinos TA. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004;36:1312-8.